Impact of Spirulina platensis supplementation on general health status of HIV infected patients in Burkina Faso

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83770226

Enrollment

180

Registered

2007-08-17

Start date

2006-05-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV / AIDS Infections and Infestations HIV / AIDS

Interventions

Group 1: 60 Patients with 200 CD4/µl of peripheric blood or lower (patients who are currently receiving antiretroviral treatment) Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HIV infected 2. At least 18 years old 3. Willing to be followed up for at least 12 months 4. Informed consent to be provided by the patient

Exclusion criteria

Exclusion criteria: 1. Patients who do not consent to be involved in the trial 2. Under the age of 18 years 3. Patients who are pregnant 4. Cardiopathy or cancer 5. Currently receiving Spirulina platensis spplementation

Design outcomes

Primary

Measure	Time frame
The impact of active daily supplementation of Spirulina platensis on the clinical, nutritional and immunological status of HIV infected patients will be assessed by the following: 1. Measurement of CD4, viral load, hematological and biochemical parameters at the start, 6 and 12 months of trial 2. Monthly measurement of anthropometric parameters	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Burkina Faso

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026